No insider purchase over the last 90 days. The latest, by 허태영, was filed 06 Jul 2026.
Who traded when
BuySale+3 other insiders
Since the insiders bought
- -9.1%Entry ₩8,500 · Close 30 Oct 2026 ₩7,730
- -42.1%Entry ₩13,340 · Close 30 Oct 2026 ₩7,730
- -42.0%Entry ₩13,320 · Close 30 Oct 2026 ₩7,730
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- 9,000 sharesShareKRXDART:20260706000071Canonical exit: 4 Oct 2026 (T+90)
- 1,370 shares@ ₩13,820.000.0056% mcap100.0% of flowShareKRXDART:20260430001807
- 89,646 shares@ ₩13,701.99310.36% mcap24.9% of flowShareKRXDART:20260407001567Canonical exit: 1 Jul 2026 (T+90)
- 349,942 sharesKRXDART:20260407001772Canonical exit: 1 Jul 2026 (T+90)
- 3,366 sharesShareKRXDART:20260403002917Canonical exit: 30 Jun 2026 (T+90)
- 186,072 shares@ ₩13,984.96170.78% mcap53.2% of flowShareKRXDART:20260327000209Canonical exit: 18 Jun 2026 (T+90)
- 74,224 shares@ ₩14,343.41560.32% mcap22.0% of flowShareKRXDART:20260318001275Canonical exit: 9 Jun 2026 (T+90)
- ●Executives0DART
- 10,000 sharesShareKRXDART:20260204000494Canonical exit: 5 May 2026 (T+90)
- 5,000 sharesShareKRXDART:20260204000520Canonical exit: 5 May 2026 (T+90)
- 10,000 sharesShareKRXDART:20260204000502Canonical exit: 5 May 2026 (T+90)
- 10,000 sharesShareKRXDART:20260102000010Canonical exit: 2 Apr 2026 (T+90)
- 25,000 sharesShareKRXDART:20251203000088Canonical exit: 3 Mar 2026 (T+90)
- 15,000 sharesShareKRXDART:20250407003450Canonical exit: 6 Jul 2025 (T+90)
- 5,100 sharesShareKRXDART:20250407003407Canonical exit: 6 Jul 2025 (T+90)
- 10,000 sharesShareKRXDART:20250407003364Canonical exit: 6 Jul 2025 (T+90)
- ●Executives0DART
- ShareKRXDART:20240823000554Canonical exit: 18 Nov 2024 (T+90)
- ShareKRXDART:20240823000565Canonical exit: 18 Nov 2024 (T+90)
- 587,400 sharesKRXDART:20240709000070Canonical exit: 30 Sept 2024 (T+90)
- ShareKRXDART:20240709000073Canonical exit: 2 Oct 2024 (T+90)
- ShareKRXDART:20240702000052Canonical exit: 24 Sept 2024 (T+90)
- ShareKRXDART:20240531000646Canonical exit: 22 Aug 2024 (T+90)
- 449,999 sharesKRXDART:20240412002067Canonical exit: 8 Jul 2024 (T+90)
- 384,687 shares@ ₩11,958.39852.6% of flowShareKRXDART:20240412002048Canonical exit: 3 Jul 2024 (T+90)
25 of 80 declarations
About EuBiologics Co., Ltd.
바이오노트 is by far the top filer at 유바이오로직스 (EuBiologics Co., Ltd.): 59 of the 80 filings, including 56 purchases. Its three largest purchases: EUR 3,137,364 on April 4, 2024, EUR 1,506,679 on March 20, 2026 and EUR 703,832 on April 2, 2026. Five purchases carry an amount, EUR 6.0 million in all (median EUR 703,832).
The record counts 69 purchases against a single sale: 99% purchases. 신정섭 (상무) signs 3, 전동운 (상무) and 장재선 (이사) 2 each. The company has 6 filings with no trade. On February 4, 2026, 3 distinct filers bought.
Read moreShow less
South Korean health care capitalised at KRW 292.3 billion, 23.8% of the capital with insiders, 13 filers. Filings, published from February 26, 2021 to July 6, 2026, are most numerous in 2021 (22) and 2022 (23), then 8, 10, 5 and 12. Publication at the median 5 days after the trade. The 13 filings of the latest year include 11 purchases and no sale.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
